Chapter 15

Transcatheter Mitral Cerclage Annuloplasty

Christopher Bruce

Christopher Bruce

Cardiovascular Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA

Search for more papers by this author
June-Hong Kim

June-Hong Kim

Division of Cardiology, Pusan National University Yangsan Hospital, Busan, Republic of Korea

Search for more papers by this author
Toby Rogers

Toby Rogers

Cardiovascular Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA

Search for more papers by this author
Robert J. Lederman

Robert J. Lederman

Cardiovascular Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA

Search for more papers by this author
First published: 12 March 2021

Summary

Functional mitral regurgitation due to annular dilation is associated with morbidity and mortality in patients with dilated cardiomyopathy of any etiology. Transcatheter cerclage mitral annuloplasty (cerclage) is a percutaneous treatment for functional mitral regurgitation that exploits the proximity of the mitral annular plane to the anatomical path of the coronary sinus (CS) in order to surround and compress the mitral annulus. This chapter summarizes the design of a mitral cerclage annuloplasty device and its performance in preclinical and first-inhuman settings. Cerclage addresses several key shortcomings of CS annuloplasty, evident in the early clinical development of devices including Carillon (Cardiac Dimensions), PTMA (Viacor), and MONARC (Edwards Lifesciences). Percutaneous cerclage annuloplasty devices are fairly simple and have three component parts: tension element, wishbone section, and wishbone lock.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.